Nicholas Medcalf

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1520165/publications.pdf

Version: 2024-02-01

1162367 1199166 12 309 8 12 citations g-index h-index papers 13 13 13 549 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Assessing the immunosuppressive activity of alginate-encapsulated mesenchymal stromal cells on splenocytes. Artificial Cells, Nanomedicine and Biotechnology, 2022, 50, 168-176.	1.9	0
2	Re-engineering the innovator–clinic interface for adoption of advanced therapies. Regenerative Medicine, 2021, 16, 295-308.	0.8	1
3	Quantifying Operator Subjectivity within Flow Cytometry Data Analysis as a Source of Measurement Uncertainty and the Impact of Experience on Results. PDA Journal of Pharmaceutical Science and Technology, 2021, 75, 33-47.	0.3	8
4	The management of risk and investment in cell therapy process development: a case study for neurodegenerative disease. Regenerative Medicine, 2019, 14, 465-488.	0.8	4
5	Redistributed manufacturing $\hat{a} \in \hat{a}$ challenges for operations management. Production Planning and Control, 2019, 30, 493-495.	5.8	7
6	Decentralised manufacturing of cell and gene therapy products: Learning from other healthcare sectors. Biotechnology Advances, 2018, 36, 345-357.	6.0	40
7	Cell therapy-processing economics: small-scale microfactories as a stepping stone toward large-scale macrofactories. Regenerative Medicine, 2018, 13, 159-173.	0.8	39
8	Centralised versus decentralised manufacturing and the delivery of healthcare products: A United Kingdom exemplar. Cytotherapy, 2018, 20, 873-890.	0.3	23
9	Decentralized manufacturing of cell and gene therapies: Overcoming challenges and identifying opportunities. Cytotherapy, 2017, 19, 1140-1151.	0.3	40
10	Putting a price tag on novel autologous cellular therapies. Cytotherapy, 2016, 18, 1056-1061.	0.3	32
11	Pullulan: a new cytoadhesive for cell-mediated cartilage repair. Stem Cell Research and Therapy, 2015, 6, 34.	2.4	38
12	A 3D bioprinting exemplar of the consequences of the regulatory requirements on customized processes. Regenerative Medicine, 2015, 10, 863-883.	0.8	54